Analysts Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $12.75

Pulmonx Co. (NASDAQ:LUNG) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.75.

A number of research firms have recently weighed in on LUNG. Wells Fargo & Company cut their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Citigroup reiterated a “neutral” rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus dropped their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Pulmonx Trading Down 3.0 %

Shares of LUNG stock opened at $6.84 on Friday. Pulmonx has a 12-month low of $5.46 and a 12-month high of $14.84. The company has a market capitalization of $270.10 million, a PE ratio of -4.65 and a beta of 0.66. The firm has a 50 day moving average price of $6.54 and a two-hundred day moving average price of $6.88. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. During the same period in the prior year, the company posted ($0.39) earnings per share. As a group, analysts predict that Pulmonx will post -1.53 earnings per share for the current year.

Insider Buying and Selling

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,376 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.18, for a total transaction of $27,043.68. Following the transaction, the insider now owns 291,057 shares in the company, valued at approximately $1,798,732.26. This represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel David Aaron Lehman sold 5,497 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.19, for a total transaction of $34,026.43. Following the completion of the transaction, the general counsel now directly owns 197,851 shares in the company, valued at $1,224,697.69. This trade represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,873 shares of company stock valued at $324,070 over the last 90 days. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of LUNG. 272 Capital LP purchased a new stake in shares of Pulmonx in the third quarter valued at about $25,000. nVerses Capital LLC purchased a new stake in Pulmonx in the 3rd quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Pulmonx during the 2nd quarter worth approximately $37,000. SG Americas Securities LLC purchased a new position in shares of Pulmonx in the 3rd quarter worth approximately $102,000. Finally, Hsbc Holdings PLC bought a new position in shares of Pulmonx in the second quarter valued at approximately $93,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.